Immatics N.V. Ordinary Shares IMTX
i
Market datapartial · fetched 2026-11-12T02:22:49.921Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:06.302814329Z
FundamentalsAlpha Vantage · unavailable
Immatics N.V. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 6.11 | 157.4% | 14.5% | |||
| 35Δ | 16.38 | 649.4% | 159.8% | 6.36 | 175.6% | 13.7% |
| 40Δ | 10.93 | 495.4% | 78.4% | 6.60 | 193.8% | 13.0% |
| 45Δ | 8.75 | 394.2% | 45.7% | 6.84 | 212.0% | 12.3% |
| 50Δ | 7.65 | 323.1% | 29.4% | 7.07 | 218.2% | 11.2% |
| 55Δ | 6.96 | 267.5% | 19.0% | 7.25 | 203.6% | 9.5% |
| 60Δ | 6.68 | 233.4% | 14.8% | 7.44 | 189.0% | 7.9% |
| 65Δ | 6.40 | 199.2% | 10.6% | 7.62 | 174.4% | 6.2% |
| 70Δ | 6.12 | 165.1% | 6.5% | 7.81 | 159.8% | 4.6% |
| 75Δ | 7.99 | 145.1% | 2.9% | |||
| 80Δ | 10.08 | 253.6% | 3.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.11
- IV
- 157.4%
- B/E move
- 14.5%
35Δ
- Pseudo strike
- 16.38
- IV
- 649.4%
- B/E move
- 159.8%
- Pseudo strike
- 6.36
- IV
- 175.6%
- B/E move
- 13.7%
40Δ
- Pseudo strike
- 10.93
- IV
- 495.4%
- B/E move
- 78.4%
- Pseudo strike
- 6.60
- IV
- 193.8%
- B/E move
- 13.0%
45Δ
- Pseudo strike
- 8.75
- IV
- 394.2%
- B/E move
- 45.7%
- Pseudo strike
- 6.84
- IV
- 212.0%
- B/E move
- 12.3%
50Δ
- Pseudo strike
- 7.65
- IV
- 323.1%
- B/E move
- 29.4%
- Pseudo strike
- 7.07
- IV
- 218.2%
- B/E move
- 11.2%
55Δ
- Pseudo strike
- 6.96
- IV
- 267.5%
- B/E move
- 19.0%
- Pseudo strike
- 7.25
- IV
- 203.6%
- B/E move
- 9.5%
60Δ
- Pseudo strike
- 6.68
- IV
- 233.4%
- B/E move
- 14.8%
- Pseudo strike
- 7.44
- IV
- 189.0%
- B/E move
- 7.9%
65Δ
- Pseudo strike
- 6.40
- IV
- 199.2%
- B/E move
- 10.6%
- Pseudo strike
- 7.62
- IV
- 174.4%
- B/E move
- 6.2%
70Δ
- Pseudo strike
- 6.12
- IV
- 165.1%
- B/E move
- 6.5%
- Pseudo strike
- 7.81
- IV
- 159.8%
- B/E move
- 4.6%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.99
- IV
- 145.1%
- B/E move
- 2.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.08
- IV
- 253.6%
- B/E move
- 3.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 154.23% | |
| 109.67% | |
| 200.34% | |
| 209.86% | |
| 139.21% | |
| 103.76% | |
| 167.81% | |
| 134.08% | |
| 111.73% | |
| 97.88% | |
| 139.83% | |
| 196.06% | |
| 200.38% | |
| 119.96% | |
| 232.23% | |
| 211.39% | |
| 92.89% | |
| 156.13% | |
| 151.96% | |
| 118.62% | |
| 132.00% | |
| 185.57% | |
| 133.95% | |
| 126.96% | |
| 123.02% | |
| 94.85% | |
| 220.32% | |
| 152.71% | |
| 154.63% | |
| 172.25% | |
| 183.43% | |
| 91.58% | |
| 162.37% | |
| 149.71% | |
| 101.48% | |
| 184.23% | |
| 107.20% | |
| 165.38% | |
| 220.94% |
Biotechnology
IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory…
More →IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York,…
More →INBX
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla,…
More →INCY
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
More →INMB
Description unavailable
More →INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases…
More →